# Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus

> **NCT06632561** · PHASE4 · COMPLETED · sponsor: **Ashraf Wasfy Beshay Aziz** · enrollment: 74 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Empagliflozin 10 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06632561
- **Lead sponsor:** Ashraf Wasfy Beshay Aziz
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-26
- **Primary completion:** 2022-03-09
- **Final completion:** 2022-03-14
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06632561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06632561, "Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06632561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*